JP2020507624A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507624A5
JP2020507624A5 JP2019563696A JP2019563696A JP2020507624A5 JP 2020507624 A5 JP2020507624 A5 JP 2020507624A5 JP 2019563696 A JP2019563696 A JP 2019563696A JP 2019563696 A JP2019563696 A JP 2019563696A JP 2020507624 A5 JP2020507624 A5 JP 2020507624A5
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
independently
groups
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507624A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2018/050342 external-priority patent/WO2018146468A1/en
Publication of JP2020507624A publication Critical patent/JP2020507624A/ja
Publication of JP2020507624A5 publication Critical patent/JP2020507624A5/ja
Pending legal-status Critical Current

Links

JP2019563696A 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用 Pending JP2020507624A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
US62/455,645 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020507624A JP2020507624A (ja) 2020-03-12
JP2020507624A5 true JP2020507624A5 (enExample) 2021-03-11

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563696A Pending JP2020507624A (ja) 2017-02-07 2018-02-07 スルフィニルピリジンおよび癌の治療におけるそれらの使用

Country Status (12)

Country Link
US (2) US11208384B2 (enExample)
EP (1) EP3580204A1 (enExample)
JP (1) JP2020507624A (enExample)
KR (1) KR20190115011A (enExample)
CN (1) CN110382465A (enExample)
AU (1) AU2018218518B2 (enExample)
BR (1) BR112019016258A2 (enExample)
CA (1) CA3051644A1 (enExample)
MA (1) MA47450A (enExample)
MX (1) MX2019009356A (enExample)
RU (1) RU2019127896A (enExample)
WO (1) WO2018146468A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CA3051644A1 (en) * 2017-02-07 2018-08-16 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
MX392900B (es) 2017-02-07 2025-03-24 Oblique Therapeutics Ab Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
MX389800B (es) 2017-02-07 2025-03-20 Oblique Therapeutics Ab Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
US20210038577A1 (en) * 2018-02-12 2021-02-11 Cinda Pharma Ab Thioredoxin reductase inhibitors for use in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE4643T1 (de) 1979-12-19 1983-09-15 Duphar International Research B.V Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen.
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
JP2002515023A (ja) 1995-08-24 2002-05-21 ビーエーエスエフ アクチェンゲゼルシャフト N−複素環化合物、その製造用中間体、それを含む組成物及び有害菌類防除にそれを使用する方法
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
WO1998054139A1 (de) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003211427A1 (en) 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
US20100048713A1 (en) 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
CA2647338A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors-3
WO2007137255A2 (en) * 2006-05-22 2007-11-29 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
EP2435040A2 (en) * 2009-05-28 2012-04-04 President and Fellows of Harvard College N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
EP2535059A4 (en) 2010-02-10 2014-03-12 Public Univ Corp Yokohama City USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF)
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
EP2811990B1 (en) 2012-02-10 2017-10-25 The Board of Regents of The University of Texas System Modulators of exchange proteins directly activated by camp (epacs)
US8946418B1 (en) 2013-07-10 2015-02-03 Boehringer Ingelheim International Gmbh Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
MX392900B (es) 2017-02-07 2025-03-24 Oblique Therapeutics Ab Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
MX389800B (es) 2017-02-07 2025-03-20 Oblique Therapeutics Ab Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
CA3051644A1 (en) * 2017-02-07 2018-08-16 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2020506244A5 (enExample)
JP2020507625A5 (enExample)
JP2020506970A5 (enExample)
JP2020533277A5 (enExample)
RU2019127896A (ru) Сульфинилпиридины и их применение при лечении рака
JP2021524838A5 (enExample)
JP2010539110A5 (enExample)
CN110016025A (zh) 一种免疫调节剂
JP2019517487A5 (enExample)
JP2008546791A5 (enExample)
RU2019128063A (ru) Углеводородсульфонилзамещенные пиридины и их применение при лечении рака
JP5855250B2 (ja) イミダゾオキサジン化合物による抗腫瘍効果増強剤
JP2016523973A5 (enExample)
RU2015124002A (ru) Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
RU2018107879A (ru) Пиридины и их применение в лечении рака
JP2012522759A5 (enExample)
JP2018532786A5 (enExample)
JP2019512535A5 (enExample)
JP2017522277A5 (enExample)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2016190843A5 (enExample)
JP2018529690A5 (enExample)
JP2020527173A5 (enExample)
JP2020507625A (ja) ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
RU2007116987A (ru) Новые соединения